v3.24.1.1.u2
Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 3,404,349 $ 1,123,604
Unbilled receivable 96,224 97,561
Prepaid expenses and other current assets 1,196,067 1,067,703
Total current assets 4,696,640 2,288,868
Other assets 377,550 419,217
Total assets 5,074,190 2,708,085
Current liabilities:    
Accounts payable 981,720 1,936,007
Accrued expenses and other liabilities 408,435 542,260
Notes payable and accrued interest 245,973 854,697
Total current liabilities 1,636,128 3,332,964
Long-term liabilities:    
Liability classified warrants 17,433 26,388
Total long-term liabilities 17,433 26,388
Total liabilities 1,653,561 3,359,352
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2024 (unaudited) and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized at March 31, 2024 (unaudited) and December 31, 2023; 7,329,253 and 3,146,157 shares issued at March 31, 2024 (unaudited) and December 31, 2023, respectively; 7,329,172 and 3,146,076 shares outstanding at March 31, 2024 (unaudited) and December 31, 2023, respectively 733 315
Additional paid-in capital 128,422,232 121,233,901
Accumulated deficit (124,673,853) (121,557,074)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) 3,749,112 (322,858)
Noncontrolling interests in stockholders’ deficit (328,483) (328,409)
Total stockholders’ equity (deficit) 3,420,629 (651,267)
Total liabilities and stockholders’ equity (deficit) $ 5,074,190 $ 2,708,085

Source

PDF HTML
ZIP XLS XBRL